Lomustine-temozolomide combination therapy versus
standard temozolomide therapy in patients with newly
diagnosed glioblastoma with methylated MGMT promoter
(CeTeG/NOA–09): a randomised, open-label, phase 3 trial
This is the results of a relatively small randomized study comparing Temodar to Temodar plus Lomustine for Newly Diagnosed GBM with MGMT methylation. Results look very good - a significant increase in overall survival - about 17 months. However, I would like to see this study repeated with a larger number of patients, and possibly include Optune use.
One problem I have is that the treatment was limited to about 6 months of therapy. Looking at the graphs, there is really no difference between the groups for the first 2 years. Only 2 patients at the end of the trial make the plots diverge. These 2 patients may have had different treatments after finishing the trial treatments or may just have been lucky.
Posted on: 02/22/2019
Click HERE to return to brain tumor news headlines